Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.